Here is a data pool of over 61,000 women with the different subsets broken down:
http://www.asco.org/ASCO/Abstracts+%...stractID=40116
triple positives accounted for just over 11% of all primary invasive breast cancers
5 year survival was much closer in % to er+pr+her2- than er-pr-her2+ (but data from 99-04)
__________________
Are we there yet?
Dx 10/05 IDC, multi-focal, triple +, 5 nodes+
MRM, 4 DD A/C, 12 weekly taxol + herceptin
rads concurrent with taxol/herceptin
finished herceptin 01/08
ooph, Arimidex, bilateral DIEP reconstruction
NED
Univ. of WA, Seattle vaccine trial '07
|